Posted at 19:57h
PHILADELPHIA, June 24, 2005
- Findings from the largest study of headache sufferers ever conducted sponsored by the National Headache Foundation were presented today. Results from the American Migraine Prevalence and Prevention (AMPP) Study indicate that 40 percent of migraine sufferers – or nearly 12 million people – could benefit from preventive therapies. Of migraine sufferers in the study, only one in five Americans currently uses preventive therapies, however, millions could benefit from these treatments. The results, presented at the 47th Annual Meeting of the American Headache Society, underscore the need for more dialogue between healthcare providers and migraine sufferers to ensure all treatment options are explored.
“The ultimate goal of every migraine patient and their healthcare provider is a life with fewer interruptions caused by migraine pain and disability,” said Richard B. Lipton, M.D., lead study researcher, professor and vice chair of neurology at the Albert Einstein College of Medicine in New York City and director of the Montefiore Headache Unit. “Preventive medications can decrease migraine occurrence by 50 to 80 percent, as well as reduce the severity and duration of migraines that do occur. Preventive treatment is considerably underused as demonstrated in this study.”